Synlogic stock.
Oct 20, 2022 · Synlogic was spun out of MIT and uses technology developed by Drs. Tim Lu and Jim Collins. Synlogic was founded in 2014 and became a public company via a reverse merger in 2017. The first ...
Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study. December …You may vote if you were the record owner of Synlogic, Inc. common stock at the close of business on April 18, 2023 (the “Record Date”). A list of registered stockholders as of the close of business on the Record Date will be available at our corporate headquarters for examination by any stockholder for any purpose germane to the Annual Meeting for a …Mar 29, 2023 · Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ... What is the target price for Synlogic (SYBX) stock? A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on Friday, August 11, 2023. The analyst firm set a price ...
Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3. October 18, 2022.CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock …
Stock Information. Stock Quote & Chart; Analyst Coverage; Corporate Governance. Governance Highlights; Management Team; Board of Directors; Committee …Nov 9, 2023 · Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options ...
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 ... Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in …Apr 28, 2023 · Synlogic (NASDAQ:SYBX) is undoubtedly a potential 10X investment, judging by its numbers alone. Shares of SYBX stock trade at only 53 cents per share, while its target stock price is $7.17 . Wall Street Stock Market & Finance report, prediction for the future: You'll find the Synlogic share forecasts, stock quote and buy / sell signals below. According to present data Synlogic's SYBX shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).
24.65%. Get the latest Synlogic Inc (SYBX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic's pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug …Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 4,025% from the current SYBX share price of $2.00. Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration. CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a ...Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuriaCAMBRIDGE, Mass., March 20 ...
The latest Synlogic stock prices, stock quotes, news, and SYBX history to help you invest and trade smarter.CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the appointment of Antoine Awad as Head of Technical Operations, and the expansion of its manufacturing capabilities to produce clinical trial …Nov 9, 2023 · Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options ... Synlogic Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Looking ahead, revenue is forecast ...Synlogic ( SYBX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 9, 2023 for Q3 and the Actual Revenue was $393K, which beat the ...
Nov 9, 2017 · Sep-22-21 11:32PM. Synlogic Announces Pricing of Public Offering of Common Stock. (PR Newswire) Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs.
Synlogic Inc SYBX Morningstar Rating Unlock Stock XNAS Rating as of Nov 17, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...Nov 29, 2023 · 2 equities research analysts have issued twelve-month price targets for Synlogic's shares. Their SYBX share price targets range from $75.00 to $90.00. On average, they anticipate the company's share price to reach $82.50 in the next year. This suggests a possible upside of 3,351.9% from the stock's current price. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (Reverse Stock Split), effective at 5:00 p.m. Eastern Time on Wednesday ...Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Find the latest Synlogic, Inc. (SYBX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...
Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November.
- Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell, Ph.D., and Richard Shea. CAMBRIDGE, Mass. & AUSTIN, …
CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low …Synlogic saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 90,800 shares, a decline of 41.7% from the previous total of 155,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment.The latest price target for . Synlogic (NASDAQ: SYBX) was reported by Chardan Capital on August 11, 2023.The analyst firm set a price target for $6.00 expecting SYBX to rise to within 12 months (a ...CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the company’s Phase 2 Synpheny-1 study for phenylketonuria (PKU) were presented in a podium presentation yesterday during the …Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 8% and 3.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept. Apr. 27. MT. Chardan Adjusts Price Target on Synlogic to $5.50 From $7, Keeps Buy Rating. Mar. 30. MT. Synlogic Rating Maintained at Buy But Price Target Lowered to $5.50 at Chardan Due to 'Higher Projected Future Share Count'. Mar. 30.Synlogic beat estimated earnings by 3.75%, reporting an EPS of $-2.57 versus an estimate of $-2.67. Revenue was down $285 thousand from the same period last year. Past Earnings PerformanceSynlogic, Inc. (SYBX) is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases. The stock price, news, quote and history of SYBX are available on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield and more.
The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts. CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low …Stock Information. Stock Quote & Chart; Analyst Coverage; Corporate Governance. Governance Highlights; Management Team; Board of Directors; Committee …Sep 27, 2023 · Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ... Instagram:https://instagram. option trading servicemacd rsi strategybest health insurance georgiaelectric company stocks Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases.See Synlogic, Inc. (SYBX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. apy vs dividend ratevwiux yield Upcoming Industry and Banking Conferences. Synlogic will participate in the banking and industry conferences listed below in early 2022. Recorded presentations will be available at https://investor.synlogictx.com.. H.C. Wainwright BIOCONNECT Virtual Conference. Synlogic will present a corporate update at the H.C. Wainwright …The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. defiance quantum etf Synlogic Stock Probability Of Bankruptcy ... Stocks USA . ... Synlogic Probability Of Bankruptcy is used to show its chance of financial distress over the next two ...Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.٣١/٠١/٢٠١٨ ... Was this some sort of “pivot”? Turns out that it's actually a secondary offering, not an IPO, and it is now an entirely new company as a result ...